Teva, GSK Want Lamictal Suit Paused To Appeal Class Cert.
By Anne Cullen ( January 4, 2019, 1:31 PM EST) -- GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. are aiming to dismantle drug wholesalers' newly secured class certification in an antitrust battle centered on the availability of generic options to brand-name epilepsy drug Lamictal, asking a New Jersey federal court Thursday to put the case on hold while they appeal the class's win....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.